3-(1H-吡唑-1-甲基)苯甲酸甲酯 | 562803-63-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(1H-吡唑-1-甲基)苯甲酸甲酯
• 英文名称: methyl 3-(1H-pyrazol-1-ylmethyl)benzoate
• 英文别名: methyl 3-(pyrazol-1-ylmethyl)benzoate
• CAS: 562803-63-8
• 化学式: C₁₂H₁₂N₂O₂
• mdl: MFCD02253850
• 分子量: 216.239
• InChiKey: DWRSIYURKMHQLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933199090

反应信息

• 作为反应物：
  描述：

  3-(1H-吡唑-1-甲基)苯甲酸甲酯 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 3-(1H-吡唑-1-基甲基)苯甲酸
  参考文献：
  名称：

  A structure–Permeability study of small drug-like molecules

  摘要：

  A systematic structure permeability relationship study on a set of small drug-like molecules with log D values in the range -2.5 to 3 and carrying a diverse Arran of functionality reveals that the compounds with log D>0 and <3 are highly permeable. Surprisingly. several tetrazole derivatives were found to be substrates for efflux pump(s). (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)01035-1
• 作为产物：
  描述：

  间氯苯甲酸甲酯 、 potassium 1-[(trifluoroboranyl)methyl]-1H-pyrazole 在 bis(η3-allyl-μ-chloropalladium(II)) 、 环戊基甲醚 、 sodium 2’-(dicyclohexylphosphino)-2,6-dimethoxy-[1,1‘-biphenyl]-3-sulfonate 、 caesium carbonate 作用下， 以 水 为溶剂， 反应 24.0h， 以61%的产率得到3-(1H-吡唑-1-甲基)苯甲酸甲酯
  参考文献：
  名称：

  Suzuki–Miyaura Cross-Coupling of Potassium Trifluoro(N-methylheteroaryl)borates with Aryl and Heteroaryl Halides

  摘要：

  The synthesis of potassium trifluoro(N-methylheteroaryl)borates and their use in cross-coupling reactions with various aryl and heteroaryl halides to construct N-methyl heteroaryl-substituted aromatic and heteroaromatic compounds are reported.

  DOI：

  10.1021/jo4009589

文献信息

• [EN] HETEROCYCLIC INHIBITORS OF GLUTAMINASE<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE GLUTAMINASE
  申请人：CALITHERA BIOSCIENCES INC

  公开号：WO2013078123A1

  公开（公告）日：2013-05-30

  The invention relates to the heterocyclic compounds of Formula (I) as defined further herein, and pharmaceutical preparations thereof. The invention further relates to methods of treating cancer, immunological or neurological diseases using the heterocyclic compounds of the invention.

  本发明涉及式(I)定义的杂环化合物及其药物制剂。本发明进一步涉及使用本发明的杂环化合物治疗癌症、免疫性或神经疾病的方法。
• HETEROCYCLIC INHIBITORS OF GLUTAMINASE
  申请人：Calithera Biosciences Inc.

  公开号：US20130157998A1

  公开（公告）日：2013-06-20

  The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.

  本发明涉及新型杂环化合物及其制药制剂。本发明还涉及使用所述新型杂环化合物治疗的方法。
• TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE
  申请人：Calithera Biosciences, Inc.

  公开号：US20150004134A1

  公开（公告）日：2015-01-01

  The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.

  本发明涉及新型杂环化合物及其制药制剂。本发明还涉及使用所述新型杂环化合物治疗或预防癌症的方法。
• Palladium-Catalyzed [5 + 2] Rollover Annulation of 1-Benzylpyrazoles with Alkynes: A Direct Entry to Tricyclic 2-Benzazepines
  作者：Alejandro Suárez-Lustres、Nuria Martínez-Yáñez、Álvaro Velasco-Rubio、Jesús A. Varela、Carlos Saá

  DOI：10.1021/acs.orglett.2c04300

  日期：2023.2.10

  first Pd-catalyzed [5 + 2] rollover annulation of 1-benzylpyrazoles with alkynes to assemble 10H-benzo[e]pyrazolo[1,5-a]azepines (tricyclic 2-benzazepines) has been developed. The rollover annulation implies a twofold C–H activation of aryl and heteroaryl Csp2–H bonds (C–H/C–H) of 1-benzylpyrazoles (five-atom partners) and alkynes to give the [5 + 2] annulated compounds.

  已开发出第一个 Pd 催化的 [5 + 2] 翻转环化 1-苄基吡唑与炔烃以组装 10 H-苯并 [ e ] 吡唑并 [1,5- a ] 氮杂（三环 2-苯并氮杂）。翻转环化意味着 1-苄基吡唑（五原子伙伴）和炔烃的芳基和杂芳基 C sp 2 -H 键 (C-H/C-H)的双重 C-H 活化，得到 [5 + 2] 环化化合物。
• Heterocyclic Inhibitors of Glutaminase
  申请人：Calithera Biosciences, Inc.

  公开号：US20200165238A1

  公开（公告）日：2020-05-28

  The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.